专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20230374116A1 SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2 审中-公开
公开(公告)号：US20230374116A1
公开(公告)日：2023-11-23
申请号：US18044897
申请日：2021-09-14
申请人： THE ROSALIND FRANKLIN INSTITUTE , OXFORD UNIVERSITY INNOVATION LIMITED , THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
发明人： Jiandong Huo , Raymond Owens , James Naismith
IPC分类号： C07K16/10 , G01N33/569 , A61P31/14
CPC分类号： C07K16/1003 , G01N33/56983 , A61P31/14 , C07K2317/569 , C07K2317/31 , C07K2317/22 , C07K2317/35 , C07K2317/76 , C07K2317/92 , G01N2333/165 , A61K2039/505
摘要： The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.

2. 发明授权

US09744188B2 Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma 有权
公开(公告)号：US09744188B2
公开(公告)日：2017-08-29
申请号：US13985629
申请日：2012-02-17
申请人： John G. Flanagan , Yingjie Shen , Edith Yvonne Jones , Alexandru Radu Aricescu , Charlotte Hannah Coles
发明人： John G. Flanagan , Yingjie Shen , Edith Yvonne Jones , Alexandru Radu Aricescu , Charlotte Hannah Coles
IPC分类号： A61K38/00 , A61K38/18 , A61K49/00 , C07K14/475 , C07K14/48 , C07K14/00 , A61K31/727 , A61K45/06 , A61K31/737 , A61K38/17
CPC分类号： A61K31/727 , A61K31/737 , A61K38/177 , A61K45/06 , A61K2300/00
摘要： Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase δ (RPTPδ), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTPδ and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTPδ. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTPδ. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.

3. 发明申请

US20160159822A1 MULTIFUNCTIONAL SUPRAMOLECULAR HYBRIDS ENCOMPASSING HIERARCHICAL SELF-ORDERING OF METAL-ORGANIC FRAMEWORK NANOPARTICLES AND METHOD OF PREPARING SAME 审中-公开
标题翻译：多功能SUPRAMOLECULAR HYBRIDS ENCOMPASSING METER-ORGANIC FRAMEWORK NANOPARTICLES的分层自我订购及其制备方法
公开(公告)号：US20160159822A1
公开(公告)日：2016-06-09
申请号：US14961961
申请日：2015-12-08
申请人： Samsung Electronics Co., Ltd.
发明人： Jin-Chong TAN , Abhijeet K. CHAUDHARI
IPC分类号： C07F1/08
摘要： A supramolecular metal-organic framework material is a reaction product of a copper compound, a trialkylamine represented by Chemical Formula 1, and benzene substituted with 3 or more carboxyl groups.
摘要翻译：超分子金属 - 有机骨架材料是铜化合物，由化学式1表示的三烷基胺和被3个以上羧基取代的苯的反应产物。

4. 发明申请

US20160077109A1 CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS 审中-公开
标题翻译：使用人类血清蛋白生物标志物的新面板进行的肝脏纤维化的临床诊断
公开(公告)号：US20160077109A1
公开(公告)日：2016-03-17
申请号：US14690539
申请日：2015-04-20
申请人： The Chancellor, Masters and Scholars of The University of Oxford
发明人： Bevin Gangadharan , Nicole Zitzmann , Raymond A. Dwek
IPC分类号： G01N33/68 , G01N33/576
CPC分类号： G01N33/6893 , G01N33/576 , G01N33/5767 , G01N2333/775 , G01N2800/085 , Y10S436/811
摘要： The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and β2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.
摘要翻译：本发明人提出了用于诊断肝纤维化和肝硬化的人类血清蛋白生物标志物的新颖小组。目前尚无可靠的非侵入性肝纤维化评估方法。使用基于2D-PAGE的蛋白质组学研究来鉴定潜在的纤维化生物标志物。分析了丙型肝炎病毒（HCV）感染引起肝脏瘢痕形成程度不同的患者血清。鉴定了与肝脏瘢痕形成和/或病毒感染相关的几种蛋白质。这些蛋白质包括α-间胰蛋白酶抑制剂重链H4片段，补体因子H相关蛋白1，CD5L，Apo L1和＆bgr; 2GPI。还检测到了分别增加和减少的a2M和补体C3的硫醇裂解。这些新型生物标志物的浓度可以使用免疫测定来确定，其中浓度将反映纤维化程度。提出了每种新型生物标志物的纤维化评分量表。所有新生物标志物的得分的添加剂结果将给出更可靠的纤维化程度的指示，而不是检查个体生物标志物。

5. 发明授权

US09222116B2 Microfluidic device and method for processing of macromolecules 有权
标题翻译：微流控装置及大分子加工方法
公开(公告)号：US09222116B2
公开(公告)日：2015-12-29
申请号：US13881102
申请日：2011-10-24
申请人： Rodolphe Marie , Anders Kristensen , Kristian Hagsted Rasmussen , Kalim Ullah Mir
发明人： Rodolphe Marie , Anders Kristensen , Kristian Hagsted Rasmussen , Kalim Ullah Mir
IPC分类号： C12M1/00 , C12M1/34 , C12M3/00 , G01N21/75 , G01N15/06 , G01N1/00 , G01N33/554 , C12P19/34 , B01L3/00 , C12Q1/68 , G01N33/487
CPC分类号： C12P19/34 , B01L3/502746 , B01L3/502761 , B01L2200/06 , B01L2300/0877 , B01L2400/086 , C12Q1/6806 , G01N33/48721 , C12Q2525/204 , C12Q2543/10 , C12Q2565/629
摘要： A microfluidic device and method for enzymatic processing of ultra-long macromolecules is accomplished using a microfluidic device a reaction chamber with a first manifold, a second manifold, and a plurality of reaction channels. Each reaction channel extends from the first manifold to the second manifold. First inlet and outlet channels fill the reaction channels via the manifolds with one or more macromolecule containers suspended in a first carrier fluid. The first inlet and outlet channels are configured such that a flow is guided through the reaction channels, and an enzymatic reagent is fed to the reaction chamber essentially without displacing the macromolecule containers trapped in the reaction channels. The second set of inlets and outlets are configured such that a flow established from the second inlet to the second outlet is guided through at least one of the manifolds and bypasses the reaction channels.
摘要翻译：用于超长大分子的酶处理的微流体装置和方法使用具有第一歧管，第二歧管和多个反应通道的反应室的微流体装置来实现。每个反应通道从第一歧管延伸到第二歧管。第一入口和出口通道经由歧管填充反应通道，其中一个或多个大分子容器悬挂在第一载体流体中。第一入口和出口通道被构造成使得流动被引导通过反应通道，并且酶试剂基本上被送入反应室而不排除被捕获在反应通道中的大分子容器。第二组入口和出口构造成使得从第二入口建立到第二出口的流被引导通过歧管中的至少一个并绕过反应通道。

6. 发明授权

US09012162B2 Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers 有权
标题翻译：使用人血清蛋白生物标志物的新型小组对肝纤维化进行临床诊断
公开(公告)号：US09012162B2
公开(公告)日：2015-04-21
申请号：US11851619
申请日：2007-09-07
申请人： Bevin Gangadharan , Nicole Zitzmann , Raymond A. Dwek
发明人： Bevin Gangadharan , Nicole Zitzmann , Raymond A. Dwek
IPC分类号： G01N33/00 , G01N33/576
CPC分类号： G01N33/6893 , G01N33/576 , G01N33/5767 , G01N2333/775 , G01N2800/085 , Y10S436/811
摘要： The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analyzed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and β2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.
摘要翻译：本发明人提出了用于诊断肝纤维化和肝硬化的人类血清蛋白生物标志物的新颖小组。目前尚无可靠的非侵入性肝纤维化评估方法。使用基于2D-PAGE的蛋白质组学研究来鉴定潜在的纤维化生物标志物。分析了丙型肝炎病毒（HCV）感染引起肝脏瘢痕形成程度不同的患者血清。鉴定了与肝脏瘢痕形成和/或病毒感染相关的几种蛋白质。这些蛋白质包括α-间胰蛋白酶抑制剂重链H4片段，补体因子H相关蛋白1，CD5L，Apo L1和＆bgr; 2GPI。还检测到了分别增加和减少的a2M和补体C3的硫醇裂解。这些新型生物标志物的浓度可以使用免疫测定来确定，其中浓度将反映纤维化程度。提出了每种新型生物标志物的纤维化评分量表。所有新生物标志物的得分的添加剂结果将给出更可靠的纤维化程度的指示，而不是检查个体生物标志物。

7. 发明申请

US20150105293A1 CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS 审中-公开
标题翻译：使用低等离子人血浆蛋白生物标志物的新面板进行的皮肤纤维化临床诊断
公开(公告)号：US20150105293A1
公开(公告)日：2015-04-16
申请号：US14521813
申请日：2014-10-23
申请人： The Chancellor, Masters and Scholars of The University of Oxford
发明人： Bevin Gangadharan , Nicole Titzmann , Raymond A. Dwek
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G01N33/5767 , G01N33/57438 , G01N33/6893 , G01N2333/47 , G01N2333/4728 , G01N2333/775 , G01N2333/924 , G01N2500/00 , G01N2800/085 , G01N2800/52 , G01N2800/54 , G01N2800/56 , G01N2800/7057
摘要： The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein.
摘要翻译：本发明人提出了用于诊断肝纤维化和肝硬化的人血浆蛋白生物标志物的新颖小组。目前尚无可靠的非侵入性肝纤维化评估方法。使用基于2D-PAGE的蛋白质组学研究来鉴定潜在的纤维化生物标志物。对丙型肝炎病毒（HCV）感染引起的肝硬化患者血浆进行了分析。鉴定了与肝脏瘢痕形成相关并且潜在地也与病毒感染相关的几种蛋白质。这些蛋白质包括14-3-3蛋白质ζ/δ，脂联素，afamin，α-1-抗胰蛋白酶，α-2-HS-糖蛋白，载脂蛋白CM，载脂蛋白E，C4b结合蛋白β链，完整/切割补体C3dg，皮质类固醇结合球蛋白，纤维蛋白原γ链，β-触珠蛋白，pH 5.46-5.49，触珠蛋白相关蛋白，血红蛋白，免疫球蛋白J链，富含亮氨酸的α-2-糖蛋白，脂质转移抑制蛋白，视黄醇结合蛋白4，血清对氧磷 /芳基酯酶1，性激素结合球蛋白和锌-α-2-糖蛋白。

8. 发明授权

US08921568B2 Iminosugars and their applications 有权
标题翻译： Iminosugars及其应用
公开(公告)号：US08921568B2
公开(公告)日：2014-12-30
申请号：US13910564
申请日：2013-06-05
申请人： Unither Virology, LLC , The Chancellor, Masters and Scholars of the University of Oxford
发明人： J. L. Kiappes , Peter Laing , Raymond Dwek , Nicole Zitzmann , Stephanie Pollock
IPC分类号： C07D401/12 , C07D211/46 , C07D405/12 , A61K31/575 , A61K31/445 , A61P31/12 , A61K31/335 , C07J43/00
CPC分类号： C07D405/12 , C07D211/46 , C07D401/12 , C07J43/003
摘要： Iminosugar compounds are described that have inbuilt delivery features by virtue of covalent incorporation of a tocopherol moiety, or alternative moieties that are analogs of tocopherol or select analogs of cholesterol, or its antagonist “Ezitimibe”; and are likely to have broad spectrum antiviral activity. The compounds differ from previous iminosugar compounds, even lipophillic ones, being more hydrophobic and resembling fats and oils in their partition behavior in vivo into lipid phases of lipoproteins, cellular lipid droplet organelles and biological membranes. These features confer a number of unique delivery attributes in vivo, favorable to the therapy of virus infections involving cells of the lymphoid system and the liver, in particular, but these features are also favorable in general for the treatment of virus infections of man and animals.
摘要翻译：描述了通过共价引入生育酚部分或作为生育酚类型或胆固醇的选择性类似物或其拮抗剂“依泽替米贝”的替代部分具有内含递送特征的亚氨基缩寡核苷酸化合物; 并且可能具有广谱抗病毒活性。这些化合物与以前的亚氨基硫糖化合物不同，甚至是脂肪细胞的化合物，更疏水，并且类似于脂肪和油在体内分泌体内成脂蛋白，细胞脂滴细胞器和生物膜的脂质相的类似物。这些特征在体内赋予许多独特的递送属性，特别是有助于涉及淋巴系统和肝细胞的病毒感染的治疗，但是这些特征对于治疗人和动物的病毒感染也是有利的。

9. 发明申请

US20140240690A1 DETERMINING EXTRINSIC CALIBRATION PARAMETERS FOR A SENSOR 有权
标题翻译：确定传感器的极限校准参数
公开(公告)号：US20140240690A1
公开(公告)日：2014-08-28
申请号：US14348482
申请日：2012-09-27
申请人： Paul Michael Newman , William Paul Maddern , Alastair Robin Harrison , Mark Christopher Sheehan
发明人： Paul Michael Newman , William Paul Maddern , Alastair Robin Harrison , Mark Christopher Sheehan
IPC分类号： G01S17/02
CPC分类号： G01S17/02 , G01S7/4808 , G01S7/4972 , G01S17/87 , G01S17/89
摘要： A method of determining extrinsic calibration parameters for at least one sensor (102, 104, 106) mounted on transportable apparatus (100). The method includes receiving (202) data representing pose history of the transportable apparatus and receiving (202) sensor data from at least one sensor mounted on transportable apparatus. The method generates (204) at least one point cloud data using the sensor data received from the at least one sensor, each point in a said point cloud having a point covariance derived from the pose history data. The method then maximises (206) a value of a quality function for the at least one point cloud, and uses (208) the maximised quality function to determine extrinsic calibration parameters for the at least one sensor.
摘要翻译：一种确定安装在可运输设备（100）上的至少一个传感器（102,104,106）的外在校准参数的方法。该方法包括：接收（202）表示可运输设备的姿势历史的数据，并从安装在可运输设备上的至少一个传感器接收（202）传感器数据。该方法使用从至少一个传感器接收的传感器数据生成（204）至少一个点云数据，所述点云中的每个点具有从姿态历史数据导出的点协方差。该方法然后使（206）至少一个点云的质量函数的值最大化，并且使用（208）最大化质量函数来确定用于至少一个传感器的外在校准参数。

10. 发明授权

US08748460B2 Iminosugars and methods of treating togaviral diseases 有权
标题翻译：伊米诺糖和治疗披膜病毒疾病的方法
公开(公告)号：US08748460B2
公开(公告)日：2014-06-10
申请号：US13761583
申请日：2013-02-07
申请人： United Therapeutics Corporation , The Chancellor, Masters and Scholars of the University of Oxford
发明人： Urban Ramstedt , Brennan Klose , Nicole Zitzmann , Raymond A. Dwek , Terry D. Butters
IPC分类号： A61K31/445
CPC分类号： A61K31/445 , Y02A50/382 , Y02A50/397 , Y02A50/409
摘要： Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.
摘要翻译：提供治疗和/或预防使用亚氨基二糖（例如DNJ衍生物）的属于披膜病毒科的病毒引起或与之相关的疾病或病症的新方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式